{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:43:15Z","timestamp":1790624595153,"version":"4.1.0"},"reference-count":48,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["31600658"],"award-info":[{"award-number":["31600658"]}]},{"name":"National Natural Science Foundation of China","award":["CIFMS-2021-I2M-5-015"],"award-info":[{"award-number":["CIFMS-2021-I2M-5-015"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["31600658"],"award-info":[{"award-number":["31600658"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS-2021-I2M-5-015"],"award-info":[{"award-number":["CIFMS-2021-I2M-5-015"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive lipid accumulation in the liver. Clarifying the molecular mechanism of lipid metabolism is crucial for the treatment of NAFLD. We examined miR-192-5p levels in the livers of mice in which NAFLD was induced via a high-fat diet (HFD), as well as in mouse primary hepatocytes and human HepG2 cells treated with free fatty acids (FFAs). MiR-192-5p inhibitor was administered to NAFLD mice and hepatocytes to verify the specific function of miR-192-5p in NAFLD. We validated the target gene of miR-192-5p and further illustrated the effects of this miRNA on the regulation of triglyceride (TG) metabolism. We found that miR-192-5p was significantly increased in the livers of NAFLD mice and FFA-treated hepatocytes. Inhibition of miR-192-5p increased the accumulation of hepatic TGs and aggravated hepatic steatosis in NAFLD mice. In FFA-treated hepatocytes, miR-192-5p inhibitors markedly increased TG content, whereas overexpression of miR-192-5p reduced TG levels. Yin Yang 1 (Yy1) was identified as the target gene of miR-192-5p, which regulates TG synthesis via the YY1\/fatty-acid synthase (FASN) pathway. Our results demonstrated that miR-192-5p should be considered a protective regulator in NAFLD that can inhibit hepatic TG synthesis by targeting Yy1.<\/jats:p>","DOI":"10.3390\/biom14010034","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T04:40:44Z","timestamp":1703565644000},"page":"34","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["MiR-192-5p Ameliorates Hepatic Lipid Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting Yy1"],"prefix":"10.3390","volume":"14","author":[{"given":"Lina","family":"Ma","sequence":"first","affiliation":[{"name":"Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China"},{"name":"Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Institute of Life Sciences (NAILS), Nanjing 210023, China"},{"name":"Research Unit of Extracellular RNA, Chinese Academy of Medical Sciences, Nanjing 210023, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichen","family":"Song","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China"},{"name":"Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Institute of Life Sciences (NAILS), Nanjing 210023, China"},{"name":"Research Unit of Extracellular RNA, Chinese Academy of Medical Sciences, Nanjing 210023, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China"},{"name":"Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Institute of Life Sciences (NAILS), Nanjing 210023, China"},{"name":"Research Unit of Extracellular RNA, Chinese Academy of Medical Sciences, Nanjing 210023, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxia","family":"Hou","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China"},{"name":"Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Institute of Life Sciences (NAILS), Nanjing 210023, China"},{"name":"Research Unit of Extracellular RNA, Chinese Academy of Medical Sciences, Nanjing 210023, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.jhep.2008.01.009","article-title":"Non-alcoholic fatty liver disease: The mist gradually clears","volume":"48","author":"Day","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"E1183","DOI":"10.1152\/ajpendo.90899.2008","article-title":"Intestinal lipid absorption","volume":"296","author":"Iqbal","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/edrv.23.2.0461","article-title":"Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes","volume":"23","author":"Lewis","year":"2002","journal-title":"Endocr. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","article-title":"Lipogenesis inhibitors: Therapeutic opportunities and challenges","volume":"21","author":"Batchuluun","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1073\/pnas.92.9.4011","article-title":"Human acetyl-CoA carboxylase: Characterization, molecular cloning, and evidence for two isoforms","volume":"92","author":"Jayakumar","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101143","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrg2290","article-title":"Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight?","volume":"9","author":"Filipowicz","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","article-title":"miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting","volume":"3","author":"Esau","year":"2006","journal-title":"Cell Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1073\/pnas.1102281108","article-title":"miR-33a\/b contribute to the regulation of fatty acid metabolism and insulin signaling","volume":"108","author":"Davalos","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.jhep.2015.07.037","article-title":"Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice","volume":"63","author":"Zhang","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.yexcr.2016.03.015","article-title":"Enhanced expression of hepatocyte-specific microRNAs in valproic acid mediated hepatic trans-differentiation of human umbilical cord derived mesenchymal stem cells","volume":"343","author":"Raut","year":"2016","journal-title":"Exp. Cell Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Tzur, G., Israel, A., Levy, A., Benjamin, H., Meiri, E., Shufaro, Y., Meir, K., Khvalevsky, E., Spector, Y., and Rojansky, N. (2009). Comprehensive gene and microRNA expression profiling reveals a role for microRNAs in human liver development. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007511"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Brunetto, M.R., Cavallone, D., Oliveri, F., Moriconi, F., Colombatto, P., Coco, B., Ciccorossi, P., Rastelli, C., Romagnoli, V., and Cherubini, B. (2014). A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110782"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1042\/CS20160216","article-title":"Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury","volume":"130","author":"Roy","year":"2016","journal-title":"Clin. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ijc.29544","article-title":"Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma","volume":"137","author":"Wen","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"Pirola","year":"2015","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0092-8674(91)90189-6","article-title":"Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein","volume":"67","author":"Shi","year":"1991","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/354241a0","article-title":"YY1 is an initiator sequence-binding protein that directs and activates transcription in vitro","volume":"354","author":"Seto","year":"1991","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"14484","DOI":"10.1073\/pnas.1008256107","article-title":"CXCR4\/YY1 inhibition impairs VEGF network and angiogenesis during malignancy","volume":"107","author":"Crudele","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.cell.2004.06.004","article-title":"Yin Yang 1 is a negative regulator of p53","volume":"117","author":"Sui","year":"2004","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13033","DOI":"10.1096\/fj.202000546R","article-title":"Betulinic acid improves nonalcoholic fatty liver disease through YY1\/FAS signaling pathway","volume":"34","author":"Mu","year":"2020","journal-title":"FASEB J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/gutjnl-2012-303150","article-title":"Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice","volume":"63","author":"Lu","year":"2014","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jcp.29043","article-title":"Lentivirus-mediated microRNA-26a-modified neural stem cells improve brain injury in rats with cerebral palsy","volume":"235","author":"Guo","year":"2020","journal-title":"J. Cell Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","article-title":"Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhep.2012.08.008","article-title":"miR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease","volume":"58","author":"Castro","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0092-8674(03)01018-3","article-title":"Prediction of mammalian microRNA targets","volume":"115","author":"Lewis","year":"2003","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lee, Y.H., Jang, H.J., Kim, S., Choi, S.S., Khim, K.W., Eom, H.J., Hyun, J., Shin, K.J., Chae, Y.C., and Kim, H. (2021). Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA. Elife, 10.","DOI":"10.7554\/eLife.70472"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1053\/j.gastro.2020.05.056","article-title":"Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122","volume":"159","author":"Chai","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/gutjnl-2016-312869","article-title":"miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression","volume":"67","author":"Hanin","year":"2018","journal-title":"Gut"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.31050","article-title":"Lipotoxic Hepatocyte-Derived Exosomal MicroRNA 192-5p Activates Macrophages Through Rictor\/Akt\/Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease","volume":"72","author":"Liu","year":"2020","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/17460441.2016.1245286","article-title":"Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors","volume":"11","author":"Angeles","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_42","first-page":"5924","article-title":"Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure","volume":"21","author":"Kley","year":"2011","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.97.7.3450","article-title":"Synthesis and antitumor activity of an inhibitor of fatty acid synthase","volume":"97","author":"Kuhajda","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1158\/0008-5472.CAN-03-3645","article-title":"Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity","volume":"64","author":"Kridel","year":"2004","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males with Metabolic Abnormalities","volume":"72","author":"Parks","year":"2020","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9804","DOI":"10.1073\/pnas.88.21.9804","article-title":"Isolation of a candidate repressor\/activator, NF-E1 (YY-1, delta), that binds to the immunoglobulin kappa 3\u2032 enhancer and the immunoglobulin heavy-chain mu E1 site","volume":"88","author":"Park","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e202000928","DOI":"10.26508\/lsa.202000928","article-title":"Multifaceted regulation of hepatic lipid metabolism by YY1","volume":"4","author":"Pan","year":"2021","journal-title":"Life Sci. Alliance"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s13577-018-0201-6","article-title":"MiR-192-5p suppresses the growth of bladder cancer cells via targeting Yin Yang 1","volume":"31","author":"Ji","year":"2018","journal-title":"Hum. Cell"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/1\/34\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:42:04Z","timestamp":1760132524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/1\/34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["biom14010034"],"URL":"https:\/\/doi.org\/10.3390\/biom14010034","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]}}}